Match!
Mary E. Schramm
Quinnipiac University
5Publications
1H-index
9Citations
Publications 5
Newest
#1Abhik Roy (Quinnipiac University)H-Index: 9
#2Mary E. Schramm (Quinnipiac University)H-Index: 1
ABSTRACT The oligopolistic nature of the U.S. pharmaceutical industry presents its members with a unique opportunity to leverage the interaction between competitive pricing strategy and promotion strategy. Previous studies have examined the role of direct-to-consumer advertising in influencing demand and sales; this study emphasizes the impact of consumer advertising on a supply-side phenomenon, the setting of prices relative to those of close competitors.
#1Eileen BridgesH-Index: 12
#2Mary E. Schramm (Quinnipiac University)H-Index: 1
Last.Abhik Roy (Quinnipiac University)H-Index: 9
view all 3 authors...
ABSTRACTThis research improves understanding of how consumers integrate their evaluations of ethical attributes with other service features in making brand choices. Although consumers appreciate brands they perceive to be ethical, few studies have examined what consumers are willing to give up in order to select a brand that offers specific ethical attributes, and under what conditions they might be willing to do so. To better characterize consumer choice, both compensatory and non-compensatory ...
#1Jennifer L. Herbst (Quinnipiac University)H-Index: 1
#2Victoria E. Richards (Quinnipiac University)
Last.Angela Mattie (Quinnipiac University)H-Index: 1
view all 4 authors...
Background A heated debate surrounds pharmaceutical companies’ proactive dissemination of information about uses of their drugs beyond those approved by the US Food and Drug Administration (FDA), a practice commonly referred to as “off-label promotion”. At the core of this debate is an underlying assumption that pharmaceutical company speech about off-label uses is inherently false and misleading and not in the best interests of patients. If, however, the companies’ off-label speech is truthful ...
#1Dandan LiuH-Index: 4
#2Xiaoling PuH-Index: 1
Last.Mary E. Schramm (Quinnipiac University)H-Index: 1
view all 3 authors...
Traditionally, firms in the pharmaceutical industry have depended on their internal research and development (R&D) capabilities to maintain a productive new product pipeline. During the past two decades, however, the industry's pipeline productivity has decreased compromising the industry's ability to meet shareholder expectations. As a strategy to invigorate pipeline productivity, and impact financial performance, pharmaceutical firms have increased utilization of strategic technical alliances....
#1Mary E. Schramm (Quinnipiac University)H-Index: 1
#2Jennifer L. Herbst (Quinnipiac University)H-Index: 1
Last.Angela Mattie (Quinnipiac University)H-Index: 1
view all 3 authors...
Purpose – The purpose of the study is to review The False Claims Act (FCA) settlements and challenges facing the industry to suggest the motivation behind firms’ alleged fraudulent activity. FCA has been applied against pharmaceutical companies by the US Government to combat marketing fraud including kickbacks, improper pricing and off-label promotion. The interests of the US Government and medical professionals are also considered. Changes to the law governing pharmaceutical marketing practices...
During the past three decades, a series of changes in the market environment have altered the structure of the pharmaceutical industry. While these changes have benefitted the generic drug sector, the effect on the branded drug sector has been detrimental. In sum, these changes have shortened the product life cycles for branded drugs by shifting market share to generic drugs sooner. As a result, it is more challenging for branded drugs to meet return on investment expectations because sales reve...
1